BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Faucheux L, Grandclaudon M, Perrot-Dockès M, Sirven P, Berger F, Hamy AS, Fourchotte V, Vincent-Salomon A, Mechta-Grigoriou F, Reyal F, Scholer-Dahirel A, Guillot-Delost M, Soumelis V. A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. Oncoimmunology 2019;8:e1624130. [PMID: 31428522 DOI: 10.1080/2162402X.2019.1624130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kok VC, Wang CCN, Liao SH, Chen DL. Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer. Breast Cancer (Dove Med Press) 2022;14:85-99. [PMID: 35437353 DOI: 10.2147/BCTT.S359346] [Reference Citation Analysis]
2 Ma YF, Chen Y, Fang D, Huang Q, Luo Z, Qin Q, Lin J, Zou C, Huang M, Meng D, Huang Q, Lu GM. The immune-related gene CD52 is a favorable biomarker for breast cancer prognosis. Gland Surg 2021;10:780-98. [PMID: 33708560 DOI: 10.21037/gs-20-922] [Reference Citation Analysis]
3 Dawod B, Liu J, Gebremeskel S, Yan C, Sappong A, Johnston B, Hoskin DW, Marshall JS, Wang J. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas. Sci Rep 2020;10:13343. [PMID: 32770025 DOI: 10.1038/s41598-020-70231-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res Treat 2021;185:261-79. [PMID: 33011829 DOI: 10.1007/s10549-020-05954-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yan C, Liu Q, Nie M, Hu W, Jia R. Comprehensive Analysis of the Immune and Prognostic Implication of TRIM8 in Breast Cancer. Front Genet 2022;13:835540. [DOI: 10.3389/fgene.2022.835540] [Reference Citation Analysis]
6 Filip-psurska B, Zachary H, Strzykalska A, Wietrzyk J. Vitamin D, Th17 Lymphocytes, and Breast Cancer. Cancers 2022;14:3649. [DOI: 10.3390/cancers14153649] [Reference Citation Analysis]
7 Li M, Xu J, Jiang C, Zhang J, Sun T. Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer. Front Oncol 2022;12:842705. [PMID: 35242718 DOI: 10.3389/fonc.2022.842705] [Reference Citation Analysis]
8 Naik A, Decock J. Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. Front Oncol 2020;10:598626. [PMID: 33324565 DOI: 10.3389/fonc.2020.598626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Karpisheh V, Ahmadi M, Abbaszadeh-goudarzi K, Mohammadpour Saray M, Barshidi A, Mohammadi H, Yousefi M, Jadidi-niaragh F. The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02528-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
10 Kuen DS, Kim BS, Chung Y. IL-17-Producing Cells in Tumor Immunity: Friends or Foes? Immune Netw 2020;20:e6. [PMID: 32158594 DOI: 10.4110/in.2020.20.e6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
11 Kok VC, Wang CC, Liao S, Chen D. Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer. BCTT 2022;Volume 14:85-99. [DOI: 10.2147/bctt.s359346] [Reference Citation Analysis]
12 Larsson C, Ehinger A, Winslow S, Leandersson K, Klintman M, Dahl L, Vallon-Christersson J, Häkkinen J, Hegardt C, Manjer J, Saal L, Rydén L, Malmberg M, Borg Å, Loman N. Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. NPJ Breast Cancer 2020;6:28. [PMID: 32656317 DOI: 10.1038/s41523-020-0170-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Akhir FNM, Noor MHM, Leong KWK, Nabizadeh JA, Manthey HD, Sonderegger SE, Fung JNT, McGirr CE, Shiels IA, Mills PC, Woodruff TM, Rolfe BE. An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer. Antibodies (Basel) 2021;10:2. [PMID: 33430104 DOI: 10.3390/antib10010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bujak JK, Szopa IM, Pingwara R, Kruczyk O, Krzemińska N, Mucha J, Majchrzak-Kuligowska K. The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors. Int J Mol Sci 2020;21:E2292. [PMID: 32225066 DOI: 10.3390/ijms21072292] [Reference Citation Analysis]
15 Tao B, Liu Y, Liu H, Zhang Z, Guan Y, Wang H, Shi Y, Zhang J. Prognostic Biomarker KIF18A and Its Correlations With Immune Infiltrates and Mitosis in Glioma. Front Genet 2022;13:852049. [DOI: 10.3389/fgene.2022.852049] [Reference Citation Analysis]